Bailey Tianheng (688506.SH): T-Bren (HER2 ADC) was used to complete the first patient enrollment in a phase III clinical trial of HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that the phase III clinical trial of HER2 positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma of HER2, an innovative biopharmaceutical independently developed by the company and whose first-line anti-HER2 treatment failed, has recently completed the enrollment of the first test subjects.

T-Bren (BL-M07D1) is an innovative ADC targeting HER2. It has best-in-class (best-in-class) potential and has shown significant anti-tumor efficacy in clinical trials. Recently, the clinical study of t-bren for HER2-positive locally advanced or metastatic gastric or gastroesophageal adenocarcinoma where first-line anti-HER2 treatment failed has entered phase III clinical trials and completed the enrollment of the first test subjects.

Up to now, T-Bren is conducting 13 clinical trials at home and abroad, including 4 phase III, 1 phase II/III, 2 phase I/II, and 3 phase I clinical trials, covering first-line and second-line HER2-positive breast cancer, HER2-positive post-operative adjuvant treatment for HER2-positive breast cancer, neo-adjuvant treatment for HER2-positive breast cancer, HER2-positive breast cancer, and HER2-positive gastric or gastroesophageal adenocarcinoma, as well as lung cancer, gastrointestinal tumors, urinary system tumors, and gynecological tumors.